Salarius Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 12.54 million compared to USD 31.61 million a year ago. Basic loss per share from continuing operations was USD 3.84 compared to USD 14.88 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5074 USD | +4.15% | -3.83% | -21.94% |
25/03 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
25/03 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.94% | 2.1M | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- SLRX Stock
- News Salarius Pharmaceuticals, Inc.
- Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023